GORE MEDICAL RECEIVES BREAKTHROUGH DEVICE DESIGNATION FOR THE GORE® EXCLUDER® THORACOABDOMINAL BRANCH ENDOPROSTHESIS
CAUTION: Investigational device. Limited by United States law to investigational use.
Apr 12, 2022
FDA Approves First Balloon Expandable Stent Graft for Use in the Iliac Artery
GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis Provides Improved Outcomes in Real-World Peripheral Arterial Disease Cases
First Patient Enrolled in GORE® TAG® Thoracic Branch Endoprosthesis Early Feasibility Study
First Early Feasibility Study of a Gore Device Will Assess Treatment of Aortic Arch Aneurysms
FDA Approves GORE® CARDIOFORM Septal Occluder for PFO Closure to Prevent Recurrent Ischemic Stroke
Gore REDUCE Clinical Study demonstrated 77 percent relative reduction in recurrent ischemic stroke when PFO closure was combined with antiplatelet therapy, compared to antiplatelet therapy alone
Gore Joins Vascular and Endovascular Leaders in Recognizing the 2014 Pioneers in Performance for North America
Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy
GORE® EXCLUDER® Iliac Branch Endoprosthesis is First Dedicated System of Its Kind Registered in Australia and New Zealand
First Successful Implants Providing Endovascular Repair to Iliac Arteries Completed in Australia
First Patient in Europe Receives Implant of GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System and Enrolls in Post-Market Registry
Investigator initiated EXCeL Registry will assess safety and abdominal aortic aneurysm treatment success in patients with challenging anatomies
Gore Launches Clinical Quality Improvement (CQI) Project of New Hernia Repair Device
New research methodology will procure real world feedback from surgeons and patients to improve outcomes with GORE® SYNECOR Biomaterial
GORE® EXCLUDER® Conformable AAA Endoprosthesis Obtains CE Mark
Continually expanding clinicians’ options in the endovascular treatment of patients with aortic disease